Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril

Anna Cargnoni, Laura Comini, Palmira Bernocchi, Tiziana Bachetti, Claudio Ceconi, Salvatore Curello, Roberto Ferrari

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

1. Angiotensin converting enzyme (ACE) inhibitors are under study in ischaemic heart diseases, their mechanism of action being still unknown. 2. The anti-ischaemic effect of trandolapril and the possible involvement of a bradykinin-modulation on endothelial constitutive nitric oxide synthase (eNOS) in exerting this effect, were investigated. 3. Three doses of trandolapril, chronically administered in vivo, were studied in isolated perfused rat hearts subjected to global ischaemia followed by reperfusion. 4. Trandolapril has an anti-ischaemic effect. The dose of 0.3 mg kg -1 exerted the best effect reducing diastolic pressure increase during ischaemia (from 33.0 ± 4.5 to 14.0 ± 5.2 mmHg; P <0.05 vs control) and reperfusion (from 86.1 ± 9.4 to 22.2 ± 4.1 mmHg; P <0.01 vs control), improving functional recovery, counteracting creatine phosphokinase release and ameliorating energy metabolism after reperfusion. 5. Trandolapril down-regulated the baseline developed pressure. 6. Trandolapril increased myocardial bradykinin content (from 31.8 ± 6.1 to 54.8 ± 7.5 fmol/gww; P <0.05, at baseline) and eNOS expression and activity in aortic endothelium (both P <0.01 vs control) and in cardiac myocytes (from 11.3 ± 1.5 to 17.0 ± 2.0 mUOD μg protein -1 and from 0.62 ± 0.05 to 0.80 ± 0.06 pmol mg prot -1 min -1; both P <0.05 vs control). 7. HOE 140 (a bradykinin B 2 receptor antagonist) and NOS inhibitors counteracted the above-reported effects. 8. There was a negative correlation between myocyte's eNOS up-regulation and myocardial contraction down-regulation. 9. Our findings suggest that the down-regulation exerted by trandolapril on baseline cardiac contractility, through a bradykinin-mediated increase in NO production, plays a crucial role in the anti-ischaemic effect of trandolapril by reducing energy breakdown during ischaemia.

Original languageEnglish
Pages (from-to)145-153
Number of pages9
JournalBritish Journal of Pharmacology
Volume133
Issue number1
Publication statusPublished - 2001

Fingerprint

trandolapril
Nitric Oxide Synthase Type III
Bradykinin
Reperfusion
Ischemia
Down-Regulation
Myocardial Contraction
Creatine Kinase
Angiotensin-Converting Enzyme Inhibitors
Cardiac Myocytes
Muscle Cells
Energy Metabolism
Endothelium
Myocardial Ischemia

Keywords

  • Angiotensin converting enzyme inhibitors
  • Anti-ischaemic effect
  • Bradykinin
  • Endothelial constitutive nitric oxide synthase
  • Trandolapril

ASJC Scopus subject areas

  • Pharmacology

Cite this

Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. / Cargnoni, Anna; Comini, Laura; Bernocchi, Palmira; Bachetti, Tiziana; Ceconi, Claudio; Curello, Salvatore; Ferrari, Roberto.

In: British Journal of Pharmacology, Vol. 133, No. 1, 2001, p. 145-153.

Research output: Contribution to journalArticle

Cargnoni, Anna ; Comini, Laura ; Bernocchi, Palmira ; Bachetti, Tiziana ; Ceconi, Claudio ; Curello, Salvatore ; Ferrari, Roberto. / Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. In: British Journal of Pharmacology. 2001 ; Vol. 133, No. 1. pp. 145-153.
@article{f7bf3f336b9445b5a8fc27dc0b078d5e,
title = "Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril",
abstract = "1. Angiotensin converting enzyme (ACE) inhibitors are under study in ischaemic heart diseases, their mechanism of action being still unknown. 2. The anti-ischaemic effect of trandolapril and the possible involvement of a bradykinin-modulation on endothelial constitutive nitric oxide synthase (eNOS) in exerting this effect, were investigated. 3. Three doses of trandolapril, chronically administered in vivo, were studied in isolated perfused rat hearts subjected to global ischaemia followed by reperfusion. 4. Trandolapril has an anti-ischaemic effect. The dose of 0.3 mg kg -1 exerted the best effect reducing diastolic pressure increase during ischaemia (from 33.0 ± 4.5 to 14.0 ± 5.2 mmHg; P <0.05 vs control) and reperfusion (from 86.1 ± 9.4 to 22.2 ± 4.1 mmHg; P <0.01 vs control), improving functional recovery, counteracting creatine phosphokinase release and ameliorating energy metabolism after reperfusion. 5. Trandolapril down-regulated the baseline developed pressure. 6. Trandolapril increased myocardial bradykinin content (from 31.8 ± 6.1 to 54.8 ± 7.5 fmol/gww; P <0.05, at baseline) and eNOS expression and activity in aortic endothelium (both P <0.01 vs control) and in cardiac myocytes (from 11.3 ± 1.5 to 17.0 ± 2.0 mUOD μg protein -1 and from 0.62 ± 0.05 to 0.80 ± 0.06 pmol mg prot -1 min -1; both P <0.05 vs control). 7. HOE 140 (a bradykinin B 2 receptor antagonist) and NOS inhibitors counteracted the above-reported effects. 8. There was a negative correlation between myocyte's eNOS up-regulation and myocardial contraction down-regulation. 9. Our findings suggest that the down-regulation exerted by trandolapril on baseline cardiac contractility, through a bradykinin-mediated increase in NO production, plays a crucial role in the anti-ischaemic effect of trandolapril by reducing energy breakdown during ischaemia.",
keywords = "Angiotensin converting enzyme inhibitors, Anti-ischaemic effect, Bradykinin, Endothelial constitutive nitric oxide synthase, Trandolapril",
author = "Anna Cargnoni and Laura Comini and Palmira Bernocchi and Tiziana Bachetti and Claudio Ceconi and Salvatore Curello and Roberto Ferrari",
year = "2001",
language = "English",
volume = "133",
pages = "145--153",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril

AU - Cargnoni, Anna

AU - Comini, Laura

AU - Bernocchi, Palmira

AU - Bachetti, Tiziana

AU - Ceconi, Claudio

AU - Curello, Salvatore

AU - Ferrari, Roberto

PY - 2001

Y1 - 2001

N2 - 1. Angiotensin converting enzyme (ACE) inhibitors are under study in ischaemic heart diseases, their mechanism of action being still unknown. 2. The anti-ischaemic effect of trandolapril and the possible involvement of a bradykinin-modulation on endothelial constitutive nitric oxide synthase (eNOS) in exerting this effect, were investigated. 3. Three doses of trandolapril, chronically administered in vivo, were studied in isolated perfused rat hearts subjected to global ischaemia followed by reperfusion. 4. Trandolapril has an anti-ischaemic effect. The dose of 0.3 mg kg -1 exerted the best effect reducing diastolic pressure increase during ischaemia (from 33.0 ± 4.5 to 14.0 ± 5.2 mmHg; P <0.05 vs control) and reperfusion (from 86.1 ± 9.4 to 22.2 ± 4.1 mmHg; P <0.01 vs control), improving functional recovery, counteracting creatine phosphokinase release and ameliorating energy metabolism after reperfusion. 5. Trandolapril down-regulated the baseline developed pressure. 6. Trandolapril increased myocardial bradykinin content (from 31.8 ± 6.1 to 54.8 ± 7.5 fmol/gww; P <0.05, at baseline) and eNOS expression and activity in aortic endothelium (both P <0.01 vs control) and in cardiac myocytes (from 11.3 ± 1.5 to 17.0 ± 2.0 mUOD μg protein -1 and from 0.62 ± 0.05 to 0.80 ± 0.06 pmol mg prot -1 min -1; both P <0.05 vs control). 7. HOE 140 (a bradykinin B 2 receptor antagonist) and NOS inhibitors counteracted the above-reported effects. 8. There was a negative correlation between myocyte's eNOS up-regulation and myocardial contraction down-regulation. 9. Our findings suggest that the down-regulation exerted by trandolapril on baseline cardiac contractility, through a bradykinin-mediated increase in NO production, plays a crucial role in the anti-ischaemic effect of trandolapril by reducing energy breakdown during ischaemia.

AB - 1. Angiotensin converting enzyme (ACE) inhibitors are under study in ischaemic heart diseases, their mechanism of action being still unknown. 2. The anti-ischaemic effect of trandolapril and the possible involvement of a bradykinin-modulation on endothelial constitutive nitric oxide synthase (eNOS) in exerting this effect, were investigated. 3. Three doses of trandolapril, chronically administered in vivo, were studied in isolated perfused rat hearts subjected to global ischaemia followed by reperfusion. 4. Trandolapril has an anti-ischaemic effect. The dose of 0.3 mg kg -1 exerted the best effect reducing diastolic pressure increase during ischaemia (from 33.0 ± 4.5 to 14.0 ± 5.2 mmHg; P <0.05 vs control) and reperfusion (from 86.1 ± 9.4 to 22.2 ± 4.1 mmHg; P <0.01 vs control), improving functional recovery, counteracting creatine phosphokinase release and ameliorating energy metabolism after reperfusion. 5. Trandolapril down-regulated the baseline developed pressure. 6. Trandolapril increased myocardial bradykinin content (from 31.8 ± 6.1 to 54.8 ± 7.5 fmol/gww; P <0.05, at baseline) and eNOS expression and activity in aortic endothelium (both P <0.01 vs control) and in cardiac myocytes (from 11.3 ± 1.5 to 17.0 ± 2.0 mUOD μg protein -1 and from 0.62 ± 0.05 to 0.80 ± 0.06 pmol mg prot -1 min -1; both P <0.05 vs control). 7. HOE 140 (a bradykinin B 2 receptor antagonist) and NOS inhibitors counteracted the above-reported effects. 8. There was a negative correlation between myocyte's eNOS up-regulation and myocardial contraction down-regulation. 9. Our findings suggest that the down-regulation exerted by trandolapril on baseline cardiac contractility, through a bradykinin-mediated increase in NO production, plays a crucial role in the anti-ischaemic effect of trandolapril by reducing energy breakdown during ischaemia.

KW - Angiotensin converting enzyme inhibitors

KW - Anti-ischaemic effect

KW - Bradykinin

KW - Endothelial constitutive nitric oxide synthase

KW - Trandolapril

UR - http://www.scopus.com/inward/record.url?scp=0034986181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034986181&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 145

EP - 153

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 1

ER -